OpenLobby.EU
Explore

Novo Nordisk A/S

Novo Nordisk is a global healthcare company specializing in treatment for serious chronic diseases.

Lobbying Activity

Meeting with Veronika Cifrová Ostrihoňová (Member of the European Parliament, Shadow rapporteur)

12 Jan 2026 · cardiovascular health

Meeting with Niels Flemming Hansen (Member of the European Parliament)

7 Jan 2026 · Pharma

Meeting with Matthias Jorgensen (Acting Director Trade) and Green Power Denmark and

3 Dec 2025 · Exchange of views on EU-US Trade Relations.

Meeting with Matthias Jorgensen (Acting Director Trade) and Green Power Denmark and

3 Dec 2025 · Exchange of views on EU-US Trade Relations.

Meeting with Tomislav Sokol (Member of the European Parliament, Shadow rapporteur) and Koninklijke Philips and Haleon

18 Nov 2025 · Health Policy

Meeting with Niels Flemming Hansen (Member of the European Parliament)

5 Nov 2025 · Pharma package

Meeting with Stine Bosse (Member of the European Parliament)

4 Nov 2025 · General Pharmaceutical Legislation

Meeting with Lucilla Sioli (Director Communications Networks, Content and Technology) and

2 Oct 2025 · AI in life sciences

Meeting with Andreas Schwarz (Cabinet of Commissioner Ekaterina Zaharieva), Elena Martines (Cabinet of Commissioner Ekaterina Zaharieva)

30 Sept 2025 · Exchange on the Scaleup Europe Fund

Meeting with Kira Marie Peter-Hansen (Member of the European Parliament) and Confederation of Danish Industry and

18 Sept 2025 · Erhvervsnetværk - Sustainability omnibus

Meeting with Kira Marie Peter-Hansen (Member of the European Parliament, Shadow rapporteur) and A.P. Møller - Mærsk A/S and

18 Sept 2025 · Roundtable on sustainability omnibus

Novo Nordisk urges EU to integrate obesity management into cardiovascular health plan

15 Sept 2025
Topic — New EU plan to address cardiovascular disease prevention, early detection, and treatment.
Message — The organization requests that the EU CVH Plan address obesity and related comorbidities as key drivers of CVD. They call for CVH Checks in primary care, establishment of CVH Centres of Excellence, and dedicated EU funding for implementation. They emphasize that behavioral policies alone are insufficient.1234
Why — This would expand the market for their obesity and cardiometabolic treatments across Europe.56
Read full response

Meeting with Andreas Schwarz (Cabinet of Commissioner Ekaterina Zaharieva), Elena Martines (Cabinet of Commissioner Ekaterina Zaharieva)

5 Sept 2025 · scaleup financing of European deeptech startups

Meeting with Sven Gentner (Head of Unit Financial Stability, Financial Services and Capital Markets Union)

25 Jun 2025 · Reporting challenges for holding and investment companies under the CSRD

Meeting with Andreas Schwarz (Cabinet of Commissioner Ekaterina Zaharieva)

25 Jun 2025 · Exchange on the structure and outreach of the Scaleup Europe Fund.

Meeting with Kira Marie Peter-Hansen (Member of the European Parliament) and Rud Pedersen Public Affairs Brussels and

13 Jun 2025 · Debate on EU competitiveness

Novo Nordisk Urges Stronger IP Protections and Streamlined Regulations

11 Jun 2025
Topic — The European Commission's Biotech Act aims to accelerate the transition of innovations to market.
Message — Novo Nordisk requests robust intellectual property frameworks, specifically ten years of data protection. They advocate for streamlining regulatory procedures to match global timelines. The company also suggests harmonizing clinical trial approvals across the EU.123
Why — Extended data protection and faster approvals would protect products and reduce investment risks.45
Impact — Generic drug manufacturers would face significantly longer delays before entering the market.6
Read full response

Meeting with Christian Ehler (Member of the European Parliament)

5 Jun 2025 · General exchange

Meeting with Vilija Sysaite (Cabinet of Executive Vice-President Stéphane Séjourné)

30 Apr 2025 · Pharma industry and potential visit to premises in DK

Meeting with Aodhán Ó Ríordáin (Member of the European Parliament)

29 Apr 2025 · General Pharmaceutical Legislation

Novo Nordisk urges stronger patent protection and regulatory simplification

16 Apr 2025
Topic — The EU is developing a strategy to enhance competitiveness in life sciences.
Message — They propose 12 years of market protection for medicines. They want to remove rules that allow others to use their patents. The company requests a single-approval model to simplify clinical trials.123
Why — Stronger intellectual property protections would help the company secure its high-risk investments.4
Impact — Generic drug manufacturers would be delayed from launching cheaper versions of medicines.5
Read full response

Meeting with Billy Kelleher (Member of the European Parliament)

8 Apr 2025 · EU Competitiveness

Meeting with Carlo Ciccioli (Member of the European Parliament, Shadow rapporteur)

3 Apr 2025 · ITRE INI on the future of Biotechnologies and Biomanufacturing

Meeting with Christian Ehler (Member of the European Parliament)

1 Apr 2025 · General exchange

Meeting with Maria Luís Albuquerque (Commissioner) and

24 Mar 2025 · Dinner at the House of Danish Industry and roundtable discussion

Meeting with Stéphane Séjourné (Executive Vice-President) and

21 Mar 2025 · - Marché intérieur - Compétitivité - Sécurité économique - Simplification - Relation USA / Europe

Meeting with Dolors Montserrat (Member of the European Parliament, Rapporteur) and European Federation of Pharmaceutical Industries and Associations

19 Mar 2025 · New EU Pharmaceutical Legislation

Meeting with Kristoffer Storm (Member of the European Parliament)

4 Mar 2025 · Pharmaceutical Industry

Meeting with Niels Flemming Hansen (Member of the European Parliament)

4 Mar 2025 · Om regulering og konkurrence

Meeting with Ekaterina Zaharieva (Commissioner) and

27 Feb 2025 · Opportunities for cooperation between the EU and India in the fields of research, innovation, Start Ups and innovation ecosystems.

Meeting with Henrik Dahl (Member of the European Parliament)

26 Feb 2025 · The Commission Work Program

Meeting with Eszter Lakos (Member of the European Parliament)

6 Feb 2025 · R&I policy, pharmaceutical sector

Meeting with Ann-Sofie Ronnlund (Cabinet of Commissioner Ekaterina Zaharieva), Elena Martines (Cabinet of Commissioner Ekaterina Zaharieva)

5 Feb 2025 · Exchange of views on life sciences research and innovation

Meeting with Marc Lemaitre (Director-General Research and Innovation)

5 Feb 2025 · Meeting with Novo Nordisk Chief Scientific Advisor to discuss how research and innovation can help Europe to meet the ambitions set out in the Competitiveness Compass.

Meeting with Morten Løkkegaard (Member of the European Parliament, Shadow rapporteur)

4 Feb 2025 · Simplification and Biotech Act

Meeting with Stine Bosse (Member of the European Parliament)

23 Jan 2025 · European pharmaceutical policy

Meeting with Stéphane Séjourné (Executive Vice-President) and

22 Jan 2025 · Economic State of play of sector

Meeting with Tomislav Sokol (Member of the European Parliament) and Align Technology, Inc.

16 Jan 2025 · Health policy

Meeting with Billy Kelleher (Member of the European Parliament)

14 Jan 2025 · Pharma Policy

Meeting with Cynthia Ní Mhurchú (Member of the European Parliament)

13 Jan 2025 · Ireland/EU Pharmaceutical Legislation

Meeting with Barry Andrews (Member of the European Parliament)

13 Jan 2025 · EU Pharmaceutical Legislation

Meeting with Nina Carberry (Member of the European Parliament)

13 Jan 2025 · EU Pharmaceutical Legislation

Meeting with Vlad Vasile-Voiculescu (Member of the European Parliament) and European Society of Cardiology

11 Dec 2024 · Introductory Meeting

Meeting with Andrea Wechsler (Member of the European Parliament) and EnBW Energie Baden-Württemberg AG

2 Dec 2024 · EU Energy and Industry Policy

Meeting with Kira Marie Peter-Hansen (Member of the European Parliament) and Ørsted A/S and

25 Oct 2024 · Speaker at network meeting with Danish companies on EU competitiveness

Meeting with Oliver Schenk (Member of the European Parliament)

9 Oct 2024 · PharmaPackage und Wettbewerbsfähifkeit

Meeting with Eszter Lakos (Member of the European Parliament)

2 Oct 2024 · Public health

Meeting with Ştefan Muşoiu (Member of the European Parliament)

25 Sept 2024 · Presentation of the company's activity in the pharmaceutical field.

Meeting with Dimitris Tsiodras (Member of the European Parliament)

24 Sept 2024 · Public health

Meeting with Yannis Maniatis (Member of the European Parliament)

24 Sept 2024 · Introductory Meeting

Meeting with Christian Ehler (Member of the European Parliament) and Association des Constructeurs Européens d'Automobiles

23 Sept 2024 · Industriepolitik allgemein

Meeting with Stine Bosse (Member of the European Parliament, Committee chair)

18 Sept 2024 · European health policy

Meeting with Stine Bosse (Member of the European Parliament)

4 Sept 2024 · European health policy

Meeting with Christian Ehler (Member of the European Parliament)

15 Aug 2024 · Industrial policy

Meeting with Kristoffer Storm (Member of the European Parliament, Shadow rapporteur)

23 Jul 2024 · Pharmaceutical regulation

Meeting with Stine Bosse (Member of the European Parliament)

16 Jul 2024 · Revision of the EU pharmaceutical legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

18 Jun 2024 · Directive on Medicinal products for human use

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

5 Apr 2024 · Directive on Medicinal products for human use

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

13 Mar 2024 · Pharma legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

8 Mar 2024 · Directive on Medicinal products for human use

Meeting with Anders Vistisen (Member of the European Parliament)

6 Mar 2024 · Pharma

Meeting with Anders Vistisen (Member of the European Parliament)

28 Feb 2024 · Pharma

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

12 Feb 2024 · Directive on Medicinal products for human use

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and MEDICINES FOR EUROPE and EuropaBio

22 Jan 2024 · Directive on Medicinal products for human use

Meeting with Stella Kyriakides (Commissioner) and

17 Jan 2024 · Meeting with Ms Camilla Sylvest, Executive Vice-President.

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

17 Jan 2024 · Directive on Medicinal products for human use

Meeting with Jörgen Warborn (Member of the European Parliament)

12 Jan 2024 · Pharmaceuticals

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

13 Dec 2023 · Medicines

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

13 Dec 2023 · Directive on Medicinal products for human use

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur)

13 Dec 2023 · Revision of Pharmaceutical Package

Meeting with Christel Schaldemose (Member of the European Parliament) and European Federation of Pharmaceutical Industries and Associations

13 Dec 2023 · EU General Pharmaceutical Legislation

Meeting with Niels Fuglsang (Member of the European Parliament)

12 Dec 2023 · EU's grønne omstilling og industripolitik

Meeting with Erik Poulsen (Member of the European Parliament)

12 Dec 2023 · Pharmaceuticals legislation etc.

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and EUROPEAN ORGANISATION FOR RARE DISEASES

30 Nov 2023 · Directive on Medicinal products for human use

Meeting with Stelios Kympouropoulos (Member of the European Parliament)

16 Nov 2023 · discussion on the General Pharmaceutical Package revision

Meeting with Sara Cerdas (Member of the European Parliament)

16 Nov 2023 · Reunião com a Novo Nordisk

Meeting with Tomislav Sokol (Member of the European Parliament, Shadow rapporteur) and Bristol-Myers Squibb Company

15 Nov 2023 · Pharmaceutical legislation

Meeting with Laura Ballarín Cereza (Member of the European Parliament, Shadow rapporteur for opinion)

15 Nov 2023 · Pharmaceutical Package (Regulation)

Meeting with Karen Melchior (Member of the European Parliament) and Confederation of Danish Industry

7 Nov 2023 · Intellectual Property Rights

Meeting with Anders Vistisen (Member of the European Parliament)

25 Oct 2023 · General pharmaceutical legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and Confederation of Danish Industry and

13 Oct 2023 · Directive on Medicinal products for human use

Meeting with Erik Poulsen (Member of the European Parliament)

6 Oct 2023 · Pharmaceuticals legislation

Meeting with Sara Cerdas (Member of the European Parliament)

6 Oct 2023 · Novo Nordisk

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and Alliance for Regenerative Medicine

20 Sept 2023 · Directive on Medicinal products for human use

Meeting with Anders Vistisen (Member of the European Parliament)

7 Sept 2023 · General pharmaceutical legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and Novartis International AG and

18 Jul 2023 · Directive on Medicinal products for human use

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

28 Jun 2023 · Directive on Medicinal products for human use

Meeting with Niels Fuglsang (Member of the European Parliament) and Ørsted A/S

20 Jun 2023 · EU's grønne omstilling

Meeting with Bergur Løkke Rasmussen (Member of the European Parliament)

7 Jun 2023 · Pharmaceutical Legislation

Meeting with Erik Poulsen (Member of the European Parliament, Rapporteur)

16 May 2023 · NCD

Meeting with Erik Poulsen (Member of the European Parliament)

19 Apr 2023 · Pharmaceuticals legislation

Meeting with Christel Schaldemose (Member of the European Parliament)

13 Dec 2022 · diabetes

Meeting with Pierre-Arnaud Proux (Cabinet of Executive Vice-President Margrethe Vestager)

6 Dec 2022 · Revision of the EU pharmaceutical legislation.

Meeting with Christel Schaldemose (Member of the European Parliament)

16 Nov 2022 · AMR

Meeting with Tomislav Sokol (Member of the European Parliament, Rapporteur)

10 Nov 2022 · European Health Data Space - EHDS

Meeting with Christel Schaldemose (Member of the European Parliament)

17 Jun 2022 · AMR

Meeting with Linea Søgaard-Lidell (Member of the European Parliament)

19 Apr 2022 · General pharmaceutical legislation

Meeting with Tom Berendsen (Member of the European Parliament, Rapporteur)

16 Feb 2022 · Industry Strategy - Meeting with APA

Meeting with Kerstin Jorna (Director-General Internal Market, Industry, Entrepreneurship and SMEs)

16 Sept 2021 · Discussion with EFPIA and Novo Nordisk on how the pharmaceutical industry could contribute to the EU's agenda for open strategic autonomy and the renewed industrial strategy and on the green transformations of the pharmaceutical sector.

Meeting with Margaritis Schinas (Vice-President) and

16 Jun 2021 · Supply chains for medicines

Meeting with Margrethe Vestager (Executive Vice-President) and H. Lundbeck A/S and LEO Pharma A/S

21 May 2021 · Industrial Strategy

Novo Nordisk calls for faster EU drug approvals and IP protection

27 Apr 2021
Topic — EU review of pharmaceutical legislation to improve access, innovation, and supply security.
Message — The company requests faster approval timelines, integration of real-world evidence, predictable intellectual property protections, and holistic assessment of chronic disease treatments. They argue current approval times lag behind the US and Japan, delaying patient access to innovation.123
Why — This would protect their development investments and allow faster market access for their products.45
Impact — Generic and biosimilar manufacturers face stricter requirements limiting competition and affordable alternatives.678
Read full response

Meeting with Christiane Canenbley (Cabinet of Executive Vice-President Margrethe Vestager), Michele Piergiovanni (Cabinet of Executive Vice-President Margrethe Vestager) and

25 Jan 2021 · Commission’s priorities for digital and industrial policy in 2021

Novo Nordisk urges EU to strengthen innovation and IP

6 Jul 2020
Topic — A new strategy aims to ensure medicine supplies and support pharmaceutical innovation.
Message — Novo Nordisk calls for a strong intellectual property framework and new health assessment rules. They also suggest modernizing clinical trials and improving the use of health data.123
Why — Robust patent systems protect their billion-euro investments and provide market certainty.4
Impact — Generic drug manufacturers could face higher barriers when trying to enter the market.5
Read full response

Response to Farm to Fork Strategy

16 Mar 2020

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: including obesity. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 77 countries and markets its products in more than 165 countries. We welcome the Farm to Fork Roadmap, which sheds light on the ever-increasing need to truly tackle Europe’s rising obesity rates with meaningful change. Obesity is a complex, chronic disease that is influenced by multiple elements, including physiological, psychological, genetic, environmental and socioeconomic factors. We are fully supportive of the objectives of the Strategy to promote sustainable food consumption, facilitating the shift towards healthy, sustainable diets, as healthy eating and physical activity must be part of any weight loss intervention. However, a prevention-only approach will not be effective in isolation, as it does not address the root causes of the disease, including biological and genetic factors, which are not linked with food intake. With policy and regulatory action focused only on food in isolation, European governments will struggle to reverse current trends in obesity: with this approach to date, obesity has tripled since 1980 in the region. Improved knowledge and education about obesity- rooted in science- is essential at all levels- amongst citizens, healthcare practitioners, governments and civil society. There are currently many gaps across Europe in knowledge about the causes, development and impacts of obesity. With a more robust evidence base, improved awareness and understanding about the disease, European governments will be better equipped to establish meaningful policy change. Novo Nordisk recommends that the Farm to Fork Roadmap: ALIGN WITH INTERNATIONAL SCIENTIFIC CONSENSUS: Align with International standards by recognising obesity as a serious chronic disease: Adopt and refer to the definition of obesity used by the World Health Organisation and recommend that Member States reflect this terminology nationally. A MORE HOLISTIC APPROACH: The Farm to Fork Roadmap should be closely interconnected with other related initiatives (Digital, Education & training, Employment, Heath policy etc.) to ensure a holistic approach addressing prevention, treatment, and long-term management is driven from the EU level. An EU ‘Mission’ on Obesity would provide the right framework for holistic and concerted action at European level. IMPROVE THE EVIDENCE BASE AROUND OBESITY: Increase research opportunities through Horizon 2020 to better understand the disease and its causes, to better inform policy decisions. IMPROVE AWARENESS & KNOWLEDGE ABOUT OBESITY: Evaluate gaps in obesity-related education and training curricula across Europe- looking at schools, universities, hospitals, and workplaces. This could be coordinated by EU Agencies such as EuroFound and Commission Services within DG Education & Culture and DG Single Market. Based on the outcomes of this analysis the European Union could develop European guidelines for implementation at national and regional level.
Read full response

Response to Europe’s Beating Cancer Plan

3 Mar 2020

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that enable us to help people defeat other serious chronic diseases, including obesity. Obesity is a key risk factor for cancer, and is associated with increased mortality from cancer. Research also shows that obesity may worsen several aspects of cancer survivorship including quality of life, cancer recurrence, and cancer progression. The disease also adds to the strain cancer is putting on healthcare systems: obesity is responsible for 9% of all treatment costs for cancers. Obesity is a complex, chronic disease that is influenced by multiple elements, including physiological, psychological, genetic, environmental and socioeconomic factors. However, Europe’s efforts have been largely focused on prevention. The results speak for themselves: In Europe obesity has tripled since 1980. No European country has witnessed a reversal of these trends. Healthy eating and physical activity must be part of any weight loss intervention, but a prevention-only approach will not be effective in isolation, as it does not address the root causes of the disease including biological and genetic factors, which are not linked with food intake. Without recognizing obesity as a serious chronic disease requiring long-term management, European Governments will struggle to reverse these trends. Leadership at EU level is key to change attitudes, behavior, and embedded prejudices against those living with obesity. With a view to reversing the current obesity trajectory and contributing to the success of Europe’s Beating Cancer Plan, Novo Nordisk recommends that the Roadmap: 1. Emphasise obesity as one of the key risk factors for cancer in Europe, addressed as part of the prevention pillar of the EU’s Beating Cancer Plan. 2. Align with International standards by recognising obesity as a serious chronic disease: Adopt and refer to the definition of obesity used by the World Health Organisation. 3. As part of the Prevention Pillar, deliver a holistic framework for harmonised National Obesity Plans, guiding the process of establishing cross-sectoral National Plans for the prevention, treatment and long-term management of obesity, as is the case for other serious chronic diseases. 4. Recommend that Member States, as part of these National Obesity Plans, adopt the World Health Organisation definition of obesity as a chronic disease. 5. Integrate specific outcomes-focused targets on reduction of obesity prevalence as part of the EU’s Beating Cancer Plan.
Read full response

Response to Commission Delegated Regulation on GMP for IMPs

10 Feb 2017

Details responsibility related to manufacturer and sponsor are not aligned to common practice of sponsor using manufacturers in the supply chain whilst providing oversight as the sponsor. The manufacturer will than have no engagement in the conduct of the trial and will not be aware of when the trial is completed or discontinued, which makes the current wordings for some articles impractical. In particular Article 8(3) Manufacturer retained responsibility and retention period tied to the study timelines, Article 10(2) requiring the manufacturer to assure the quality control laboratory compliance, an activity that the sponsor may outsource, Article 11(1) stipulating that samples must be held by the manufacturer with no opportunity for these to be transferred to the sponsor, plus the period of retention wording, Article 12(2) tying the retention of the batch registers to the date of trial completion or discontinuation, which the manufacturer may not be aware of, Article 14(2) responsibility for unblinding solely with the manufacturer whereas in practice it is far more likely to be addressed by the sponsor. Process validation : Article 9(3), describe that validation of the manufacturing process should be to the full extent, taking into account the stage of product development. This wording is open to interpretation and not aligned with current regulatory expectations. We recommend to clarify that the manufacturing process should be appropriately controlled and monitored to assure the quality required for the intended use, taking into account the stage of product development. Critical process steps shall be validated and regularly revalidated. Manufacture in third countries: The current wording expects third country manufacturing sites to be ‘entitled’ (Wheras (5)) or ‘authorised’ (Article 3(2)) to manufacture IMPs in that third country. However, not all third countries have specific requirements for the authorisation of IMP manufacturing sites (for example USA). We suggest the wording to be changed continuing the current practice of QP declaration at the time of clinical trial application and QP responsibility for batch certification. Training of Personnel “Article 6 (4) personnel to receive training covering the theory and application of the concept of pharmaceutical quality. The manufacturer shall verify the effectiveness of the training”, is somehow unclear on what training is expected on top of training for Good Manufacturing Practices. A clarification would be appreciated.
Read full response